




Forward Looking Statements

This presentation includes statements relating to the Senhance® Surgical System's market development and a general corporate update for Asensus Surgical. These statements and other statements regarding our future plans and goals constitute "forward-looking" statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether we can successfully advance our Performance-Guided Surgery™ initiative, the market development activities related to the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons will increase, the success and market opportunity of our products, the impact of the ongoing pandemic on our business and our customers, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.





We believe in digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery.

The Reality of Surgery

1 in 5 patients undergoing surgery has 1 or more complications*





Overall profit margin decreased from 5.8% for patients without complications to 0.1% for patients with complications.**

Essentially, hospitals make no money if there is a complication.





We Expect More From Surgery

The Future
Requires Different
Capabilities
and a Holistic
Approach.

Asensus is
Uniquely
Positioned to
Deliver This.

- Increase safety for better outcomes which lead to better patient and provider satisfaction
- Reduce surgical variability and factors that contribute to poor outcomes
- Guide surgeons to successfully navigate when unexpected events occur to effectively reduce surgical errors and complications
- Provide real-time clinical intelligence and capabilities to create more predictable outcomes to meet value-based care constraints





Senhance Surgical System: Surgery Reimagined

Building The Bridge From Laparoscopy To Performance-Guided Surgery





Digitizing the Interface Between Surgeon and Patient

Delivering **Digital Laparoscopy** By Maintaining Familiar Motion, Tools, and Techniques



3DHD Visualization

 Provides surgeon with additional perception regarding depth and spatial recognition

Eye-Tracking Camera Control

- Camera movement controlled by surgeon's eye gaze
- Eliminates the need to manually adjust camera during a procedure

Haptic Feedback

- Only available on Senhance
- Natural sensation of pressure and tension
- Real-time sensory feedback
- Unparalleled level of safety




Digitizing Laparoscopic Instrumentation

Broad Instrumentation Portfolio Adds Unique Advantages For Surgeons And Patients

Core Laparoscopic

Broad portfolio of robotic lap instruments



- 70+ instruments
- Wide applicability
- Fully Reusable

3mm

A new standard in robotic MIS



- Only platform with 3mm
- Reduction in invasiveness
- Potential reduction in post-operative pain
- Enables pediatric surgery

Articulating

Access to difficult-toreach anatomy



- Two additional degrees of freedom
- Wrist-like manipulation
- Key surgeon preference item

Ultrasonic

Providing precise advanced energy



- Effectively ligate and divide tissue
- Minimizes injury to anatomy





Compelling Hospital Economics


Purpose-built solution to drive down per-procedure costs associated with robotics

Reducing Per-Procedure Costs

- Fully reusable instruments enable lower per-procedure economics:
 - In-line with traditional laparoscopy
 - Significantly lower than competing robotic systems
- O.R. time in line with competitive robotic systems

Flexible System Costs

- Multiple system acquisition economic models:
 - Leasing and lease-to-buy options available
 - Competitive robotic system cost





Robust Global Applicability


>16 Million Global Annual Addressable Procedure Market

	United States FDA Approved	European Union CE Marked	Japan PMDA Approved	Rest of World Russia, Taiwan, Others
Senhance System	\otimes	\bigcirc	\bigcirc	\bigcirc
Intelligent Surgical Unit	\bigcirc	\bigcirc	\bigotimes	\bigotimes
Procedural Indications for Use General	\bigcirc	\bigcirc	\bigcirc	\bigcirc
GYN	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Thoracic*		\bigcirc	\bigcirc	\bigcirc
Pediatric		\bigcirc	\bigcirc	
Urology		\bigotimes	\bigcirc	



Performance-Guided Surgery (PGS)

Improving Decision Making, Collaboration, and Predictability





Clinical Intelligence Powering Peak Performance

PGS Improves Decision Making, Collaboration, and Predictability



Intra-Op: Perceptive Real-Time Guidance

- · Real-Time, Intra-Op Data
- Robotic Intervention
- Reduced Cognitive Load



Pre-Op: Intelligent Preparation

- Setup Assistance
- OR Workflow
- Administrative Dashboard

Performance-Guided Surgery





- Actionable Assessments
- Digital Replay
- Trend Analysis and Benchmarking






ISU: The First Machine Vision System In Minimally Invasive Surgery

Laying The Foundation For Digitizing Surgery → Enabling The Future of Performance-Guided Surgery




1st ever augmented intelligence system to deliver real-time intraoperative digital tools to surgeons

- Enhanced camera control
- 3D measurement
- Digital tagging
- Image enhancement



Vision Based Real-Time 3D Point to Point Measurement



Real-Time Defect Identification and Sizing



ISU – Intelligent Surgical Unit ™, Some features are still in development and the safety or effectiveness of these features have not been establishe

Our Path To Market Leadership

Delivering A New Era In Digital Surgery

- 1 Educate surgeons on the benefits of Senhance
- 2 Increase global procedure volumes

- 3 Advance digital capabilities through data collection & analysis
- 4 Expand the portfolio





Educating Surgeons On The Benefits Of Senhance

Grow Compelling Set of Data to Demonstrate Clinical and Economic Value

peer review articles to date Focused on the following data:

- Health economics
 - Cost per procedure
 - Procedure times/workflow
- Usability across specialties
- Clinical outcomes

The TransEnterix European Patient Registry for Robotic-Assisted Laparoscopic Procedures in Urology, Abdominal, Thoracic, and Gynecologic Surgery ("TRUST")

Megumi Sasaki 1, Vasumitsu Hir

Dietmar Stephan 1 8, 16 Short-term results of robot-assisted colorectal Affiliations + expand cancer surgery using Senhance Digital Laparoscopy PMID: 33513657 DOI: 1 System

Abstract

da Vinci® System (Intuit Affiliations + expand monopoly for years after PMID: 35484860 PMCID: PMCI Morrisville, North Carolin movements and is desig

natients after different vi with the Senhance™ digi Abstract

Materials and methods Background: The Senhance Dig PMIID: 34591213 DOI: 10.1007/s10029-021-02510-9 and bilateral), cholecyste robot following the da Vinci Sur in Europe between Febr, colorectal cancer surgery cases | Abstract

Megunu Jasaki ", Vasumitsu Pili Takatsugu Fujii ¹, Naoto Okazai Inguinal hernia TAPP repair using Senhance [®] robotic Introduction: Robotics Hiroshi Sato 1, Shinichi Sakuran platform: first multicenter report from the TRUST registry

> N E Samalavicius 1 2 1, A Dulskas 4 5, A Sirvys 6, V Klimasauskiene 7, V Janusonis 1 3, T Janusonis 8 9, V Eismontas 1, O Deduchovas 1, D Stephan 10, I Darwich 10, C Poth 11. F Schilcher 11, Y Slabadzin 12, M Kukharchuk 12, F Willeke 10, L Staib 11


Purpose: The purpose of this article was to provide feasibility and safety results of robotic Materials and methods: We rel transabdominal preperitoneal inquinal hemia repair (Robotic TAPP).

outcomes of SS patients who ur Methods: We included 271 cases of robotic inguinal hernia TAPP repair using the Senhance® robotic Results: The median age was 71 platform from four different centers between March 2017 and March 2020. Key data points were mass index was 23.1 kg/m2. Fift intrapperative and postoperative complication rate, operating time, length of hospital stay, surgical technique was ileocecal postoperative pain score and time required to get back to a daily routine that were inserted in the ത്തെ പ്രവാദ്യം വാര്യം വാര്യം വാര്യം വാര്യം Parient Registry for Robotic assisted Laparoscopic Procedures in Urology, Abdominal Surgery, Thoracic and Gynecologic Surgery (TRUST).

> Results: We report 203 cases of unilateral and 68 cases of bilateral inquinal hernia repairs. Mean operative time was 74 ± 35 min (range 32-265 min), postoperative complications occurred in five (1.85%) cases, the intraoperative complication rate was five (1.85%). The average subjective patient

International Journal of Medical Robotics (Apr 2021)

Senhance surgical system in benian hysterectomy: A real-world comparative assessment of case times and instrument costs versus da Vinci robotics and laparoscopic-assisted vaginal hysterectomy procedures



- Senhance per procedure costs were less than half of da Vinci
- Senhance per procedure costs were in line with laparoscopy
- Case times between Senhance and da Vinci were comparable






Increasing Global Procedure Volumes

Senhance Demonstrating Strong Clinical Performance Across The Three Major Geographies

GLOBAL CLINICAL CASE VOLUME TREND



1H 2022 CASE MIX



Accelerating procedure volumes

■ EMEA ■ U.S. ■ Asia

Utilization across multiple specialty areas, demonstrating broad applicability and adoption








Advancing Digital Capabilities Through Data Collection & Analysis

Increasing Surgical Data Improves Clinical Insight and Drives Consistently Superior Outcomes

Performance-Guided Surgery

Augmented Intelligence & Deep Learning Engine








Expanding The Portfolio

Broadening Applicability Through Digital Technology, Regulatory And Instrument Expansion





2022 Business Update



2022 Q2 Performance

- 670 procedures were performed globally +34% year-over-year
 - EMEA region: +77% year-over-year
- Revenue: \$1.1 million
- Five systems installed year-to-date⁽¹⁾

- Balance Sheet Highlights
 - Cash, cash equivalents, short-term and long-term investments \$103.8 million
 - No Debt

(1): Includes one system installed during 2022 for which a Senhance System program was initiated during 2021





Asensus Surgical (NYSE American: ASXC)

Early-Commercial Stage Company Developing the Future of Surgery





1st

eye-sensing camera control
haptic feedback
3 mm robotic instruments
augmented intelligence and machine vision
real-time surgical image analytics
pediatrics with robotic 3 mm



Compelling Per Procedure Economics

*Augmented Intelligence



7,300+
Surgeries
Performed



100+ Active Surgeon Users



6 Global Training Centers



Asensus Surgical

NYSE American: ASXC

Information for Investors

Visit our IR Website:

ir.asensus.com/

IR Contact:

invest@asensus.com

Sign Up for IR Email Alerts:

ir.asensus.com/email-alerts

Follow Us On Social Media



www.linkedin.com/company/asensus-surgical-inc



twitter.com/AsensusSurgical



youtube.com/c/transenterix



vimeo.com/asxc

Clinical Resources

Visit our Corporate Website:

asensus.com/

Explore Senhance:

senhance.com/us/home

Find Clinical Data:

senhance.com/us/resources

